Premature Infants (Born BEFORE 37 Weeks) Diagnosed With Short Bowel Syndrome (SBS) After Being Given Similac® Are Urged To Get A FREE Case Examination For Justice–Complete With Financial Compensation

Premature Infants (Born BEFORE 37 Weeks) Diagnosed With Short Bowel Syndrome (SBS) After Being Given Similac® Are Urged To Get A FREE Case Examination For Justice–Complete With Financial Compensation

Families of these victims should know that manufacturers failed to reveal that premature infants (born BEFORE 37 weeks) who were fed cow’s milk–based formulas might develop short bowel syndrome (SBS)--and, those victims deserve justice. 

Those families impacted may be eligible if they were:

  • Born prematurely (before 37 weeks);
  • Fed Similac® or Enfamil® in the hospital;
  • Diagnosed with short bowel syndrome (SBS); and,
  • Experienced other serious medical conditions that may include surgeries to repair intestinal perforations, necrotizing enterocolitis, brain damage, and more

FREE CLAIM REVIEW

By clicking the "SUBMIT" button, I consent to receive recurring auto dialed and/or pre-recorded telemarketing calls and/or text messages from Shield Legal LP or our partners in order to discuss my legal options and at the telephone number I provided. I also consent to the Shield Legal LP Privacy Policy and Terms of Use. I understand that I may receive a call even if my telephone number is listed on a Do Not Call list and that my consent is not a requirement of purchase. I understand that my telephone company may impose charges on me for these contacts and that I can revoke this consent at any time. For SMS campaigns: Text STOP to cancel and HELP for help. Msg & data rates may apply. Recurring msgs up to 27 msgs per month.

100% confidential Case Evaluations

Answer a few basic questions to get started

Receive a confidential case evaluation

Have an individual claim filed for compensation

How Is Short Bowel Syndrome (SBS) Connected To Baby Formula?

National studies demonstrated how the potential for developing short bowel syndrome (SBS) in premature infants (before 37 weeks) increases with cow’s milk-based infant formula, while decreasing with breast milk.

Short bowel syndrome (SBS) is a condition affecting individuals who lose the use of a major part of their small intestine–and this condition can also be found particularly in premature infants (before 37 weeks) who have been given milk-based infant formulas such as Similac® or Enfamil® in the hospital.

This syndrome often occurs after milk-based infant formulas force the premature infants (before 37 weeks) to undergo bowel resection surgery, in which a portion of the intestine is removed.

After bowel surgery, patients–especially premature infants (before 37 weeks)--often have difficulty absorbing all of the nutrients they need.

Short bowel syndrome (SBS) symptoms essentially originate from the inability to absorb essential nutrients from food, including:

  • abdominal bloating
  • vomiting
  • abdominal pain
  • failure to gain weight
  • dehydration
  • diarrhea
  • vitamin and mineral deficiencies

According to the  U.S. National Library of Medicine, short bowel syndrome (SBS) is the most common cause of intestinal failure in infants. With necrotizing enterocolitis, gastroschisis, intestinal atresia and intestinal malrotation/volvulus being the leading causes of SBS in neonates and young infants.

iStock-174680328

Short Bowel Syndrome (SBS) Cases In The News

Similac formula lawsuit filed by mother of premature baby diagnosed with NEC, Left with Short Bowel Syndrome
September 2021

A complaint was filed in the U.S. District Court for the Southern District of Illinois indicating parents were misled that Similac® Pro-Advance was “close” to breast milk.
September 2021

A suit, filed in the Eastern District of California, alleges that the companies failed to adequately warn parents and medical professionals of the dangers of feeding their formulas to preterm and underweight babies.
May 2021

Please seek the advice of a medical professional before making health care decisions. This advertisement is not associated with Enfamil®, Similac®, or any government agency.